PD-L1/CD47 BsAb (Hanmi)

N/A

Report date: 2022/02/23 18:12:46

Base Information

Drug NamePD-L1/CD47 BsAb (Hanmi)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers

TargetsCluster of differentiation 47Programmed death-ligand 1

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHanmi Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A